Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Biomarkers, Pharmacological
/ analysis
Breast Neoplasms
/ drug therapy
Cell Cycle
/ drug effects
Cyclin-Dependent Kinase 4
/ antagonists & inhibitors
Cyclin-Dependent Kinase 6
/ antagonists & inhibitors
Piperazines
/ pharmacology
Protein Kinase Inhibitors
/ pharmacology
Purines
/ pharmacology
Pyridines
/ pharmacology
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
CDK4/6 inhibitors
cancer
cell cycle
cyclin-dependent kinase
hormone receptors
hormone therapy
metastatic breast cancer
therapies
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 09 2020
04 09 2020
Historique:
received:
31
07
2020
revised:
02
09
2020
accepted:
03
09
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast cancer lending support to the development of drugs targeting the cell cycle control machinery, like the inhibitors of the cycline-dependent kinases (CDK) 4 and 6. Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. These agents have been effective in improving the clinical outcomes, but the development of intrinsic or acquired resistance can limit the efficacy of these treatments. Clinical and translational research is now focused on investigation of the mechanism of sensitivity/resistance to CDK4/6 inhibition and novel therapeutic strategies aimed to improve clinical outcomes. This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new biomarkers of response, and the biological rationale for new combination strategies of treatment.
Identifiants
pubmed: 32899866
pii: ijms21186479
doi: 10.3390/ijms21186479
pmc: PMC7554788
pii:
doi:
Substances chimiques
Biomarkers, Pharmacological
0
Piperazines
0
Protein Kinase Inhibitors
0
Purines
0
Pyridines
0
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Oncol. 2018 Mar 1;29(3):640-645
pubmed: 29236940
Cancer Lett. 2019 Apr 10;447:130-140
pubmed: 30677445
Cancer Treat Rev. 2017 Nov;60:130-138
pubmed: 28961554
J Clin Oncol. 2019 Jan 20;37(3):178-189
pubmed: 30523750
Nature. 1993 Dec 16;366(6456):704-7
pubmed: 8259215
Cancer Cell. 2016 Mar 14;29(3):255-269
pubmed: 26977878
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Breast Cancer Res. 2020 Aug 14;22(1):89
pubmed: 32795346
Ann Oncol. 2018 Dec 1;29(12):2334-2340
pubmed: 30307466
Cancer Cell. 2002 Aug;2(2):103-12
pubmed: 12204530
NPJ Precis Oncol. 2019 Jul 16;3:18
pubmed: 31341951
Trends Cell Biol. 2018 Nov;28(11):911-925
pubmed: 30061045
Cells. 2019 Apr 06;8(4):
pubmed: 30959874
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
J Cell Sci. 2008 Dec 1;121(Pt 23):3853-7
pubmed: 19020303
N Engl J Med. 2015 Oct 22;373(17):1672-3
pubmed: 26488700
Clin Cancer Res. 2020 Jan 1;26(1):110-121
pubmed: 31527167
Crit Rev Oncol Hematol. 2017 Jun;114:91-101
pubmed: 28477750
Drug Metab Dispos. 2015 Sep;43(9):1360-71
pubmed: 26149830
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Oncologist. 2016 Oct;21(10):1165-1175
pubmed: 27368881
J Natl Cancer Inst. 2012 Mar 21;104(6):476-87
pubmed: 22302033
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Nat Rev Cancer. 2008 Sep;8(9):671-82
pubmed: 18650841
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Clin Cancer Res. 2017 Feb 15;23(4):1012-1024
pubmed: 28151717
Breast Cancer Res. 2018 Oct 19;20(1):123
pubmed: 30340505
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Curr Oncol Rep. 2019 Feb 26;21(3):25
pubmed: 30806829
Mol Cell Biol. 1995 May;15(5):2672-81
pubmed: 7739547
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Trends Biochem Sci. 1995 May;20(5):187-90
pubmed: 7610482
Breast Cancer Res. 2013 Jan 21;15(1):R5
pubmed: 23336272
Lancet Oncol. 2019 Nov;20(11):1587-1601
pubmed: 31575503
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Clin Breast Cancer. 2019 Dec;19(6):399-404
pubmed: 31235441
Lancet. 2020 Mar 7;395(10226):817-827
pubmed: 32145796
Genome Biol. 2014;15(6):122
pubmed: 25180339
Lancet Oncol. 2020 Jan;21(1):33-43
pubmed: 31838010
Clin Cancer Res. 2014 Jul 15;20(14):3763-74
pubmed: 24850847
Oncogene. 1996 Jan 4;12(1):127-34
pubmed: 8552383
Front Cell Dev Biol. 2019 Feb 26;7:23
pubmed: 30863749
J Hematol Oncol. 2017 Apr 24;10(1):97
pubmed: 28438180
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Breast Cancer Res Treat. 2020 Sep;183(2):419-428
pubmed: 32683565
Mol Cancer Ther. 2020 Aug;19(8):1575-1588
pubmed: 32546660
Cell. 1995 May 5;81(3):323-30
pubmed: 7736585
Genes Dev. 2002 Jan 15;16(2):245-56
pubmed: 11799067
Clin Cancer Res. 2017 Jun 1;23(11):2856-2868
pubmed: 27986745
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
Cancer Imaging. 2018 Jan 18;18(1):2
pubmed: 29347968
Clin Cancer Res. 2020 Mar 15;26(6):1208-1212
pubmed: 31649043
J Cancer. 2019 Aug 29;10(22):5504-5517
pubmed: 31632494
Crit Rev Oncol Hematol. 2017 Apr;112:208-214
pubmed: 28325261
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
Clin Cancer Res. 2020 Feb 1;26(3):566-580
pubmed: 31615937
Cancer Biol Ther. 2002 May-Jun;1(3):226-31
pubmed: 12432268
Sci Rep. 2018 May 22;8(1):8010
pubmed: 29789630
Clin Cancer Res. 2015 Jul 1;21(13):2905-10
pubmed: 25941111
Cancer Cell. 2014 Jul 14;26(1):136-49
pubmed: 25002028
Breast Cancer Res Treat. 2019 Nov;178(1):57-62
pubmed: 31346846
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Cancer Res. 2010 Apr 15;70(8):3228-38
pubmed: 20354191
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
Breast. 2017 Aug;34:1-11
pubmed: 28448864
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Lancet Oncol. 2020 Jun;21(6):763-775
pubmed: 32353342
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Ther Adv Med Oncol. 2018 Dec 17;10:1758835918818346
pubmed: 30619511
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):891-900
pubmed: 30130984
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Oncol Rep. 2012 Dec;28(6):2163-9
pubmed: 23023313
Lancet Oncol. 2018 Feb;19(2):249-256
pubmed: 29326029
NPJ Breast Cancer. 2020 Jun 5;6:19
pubmed: 32550264
Cell Cycle. 2012 Nov 1;11(21):3913
pubmed: 23032266
Nat Rev Clin Oncol. 2013 Apr;10(4):191-210
pubmed: 23459626
J Clin Oncol. 2018 Mar 20;36(9):884-890
pubmed: 29373071
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Cell Cycle. 2013 Mar 15;12(6):935-43
pubmed: 23421998
Genes Cancer. 2014 Jul;5(7-8):261-72
pubmed: 25221644
Breast Cancer Res Treat. 2019 Apr;174(3):615-625
pubmed: 30607633
J Biol Chem. 2012 Aug 17;287(34):29075-87
pubmed: 22733811
Sci Rep. 2019 Sep 10;9(1):13014
pubmed: 31506466
Biochem J. 2008 Dec 15;416(3):375-85
pubmed: 18925875
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Nature. 2004 Nov 18;432(7015):298-306
pubmed: 15549091
JAMA Oncol. 2019 Sep 29;:
pubmed: 31563959
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Science. 1996 Dec 6;274(5293):1672-7
pubmed: 8939849
Cancer Treat Rev. 2018 Jun;67:10-20
pubmed: 29751334
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Cancer Ther. 2016 Oct;15(10):2273-2281
pubmed: 27496135
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Mol Cancer Res. 2018 Oct;16(10):1454-1457
pubmed: 29934327
Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451
pubmed: 30038670
Oncologist. 2017 Sep;22(9):1039-1048
pubmed: 28706010
Nat Genet. 2019 Feb;51(2):207-216
pubmed: 30531871
Development. 2013 Aug;140(15):3079-93
pubmed: 23861057